The local and global relations between Σ⋆\Sigma_\star , ΣSFR\Sigma_{\rm SFR} and Σmol\Sigma_{\rm mol} that regulate star-formation

Star-formation is one of the main processes that shape galaxies, defining its stellar population and metallicity production and enrichment. It is nowadays known that this process is ruled by a set of relations that connect three parameters: the molecular gas mass, the stellar mass and the star-formation rate itself. These relations are fulfilled at a wide range of scales in galaxies, from galaxy wide to kpc-scales. At which scales they are broken, and how universal they are (i.e., if they change at different scales or for different galaxy types) it is still an open question. We explore here how those relations compare at different scales using as proxy the new analysis done using Integral Field Spectroscopy data and CO observations data from the EDGE-CALIFA survey and the AMUSSING++ compilation.Comment: 8 pages, 3 figures, 1 table, proceedings of the IAU Symposium 373: Resolving the Rise and Fall of Star Formation in Galaxie

Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children

Objectives: To evaluate a heterologous vaccination scheme in children 3-18 years old (y/o) combining two SARS-CoV-2r- receptor binding domain (RBD)protein vaccines. Methods: A phase I/II open-label, adaptive, and multicenter trial evaluated the safety and immunogenicity of two doses of FINLAY-FR-2 (subsequently called SOBERANA 02) and the third heterologous dose of FINLAY-FR-1A (subsequently called SOBERANA Plus) in 350 children 3-18 y/o in Havana Cuba. Primary outcomes were safety (phase I) and safety/immunogenicity (phase II) measured by anti-RBD immunoglobulin (Ig)G enzyme-linked immunoassay (ELISA), molecular and live-virus neutralization titers, and specific T-cells response. A comparison with adult immunogenicity and predictions of efficacy were made based on immunological results. Results: Local pain was the unique adverse event with frequency >10%, and none was serious neither severe. Two doses of FINLAY-FR-2 elicited a humoral immune response similar to natural infection; the third dose with FINLAY-FR-1A increased the response in all children, similar to that achieved in vaccinated young adults. The geometric mean (GMT) neutralizing titer was 173.8 (95% confidence interval [CI] 131.7; 229.5) vs Alpha, 142 (95% CI 101.3; 198.9) vs Delta, 24.8 (95% CI 16.8; 36.6) vs Beta and 99.2 (95% CI 67.8; 145.4) vs Omicron. Conclusion: The heterologous scheme was safe and immunogenic in children 3-18 y/o. Trial registry: https://rpcec.sld.cu/trials/RPCEC0000037